VH4127 (TFA)

VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR[1][2].

12352209

LDLR

Metabolic Enzyme/Protease

Metabolic Disease

98.67

O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@H](C(SSC[C@@H](NC(CC)=O)C(N[C@@H](CCSC)C(N1[C@H]2CSC1)=O)=O)(C)C)C(N)=O)=O)=O)=O)[C@H](CCCNC(N)=N)NC2=O.OC(C(F)(F)F)=O.[x]

C40H71N15O9S4.xC2HF3O2

1034.35 (free base)

[1]Xue Yang, et al. Preparation and In Vitro Validation of a Cucurbit[7]uril-Peptide Conjugate Targeting the LDL Receptor. J Med Chem. 2023 Jul 13;66 (13) :8844-8857.|[2]Angélina Acier, et al. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol. 2021 Aug 19;4 (1) :987.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10697A/

Peptides

No Development Reported